Dual Cholesterol Measures May Improve Heart Risk Prediction
A study has found that higher levels of non-HDL cholesterol and apolipoprotein B (ApoB) are linked to increased risks of cardiovascular disease and heart attacks. The research suggests that assessing both markers together may enhance risk prediction beyond using either one alone. The findings indicate that future cholesterol guidelines could benefit from this dual assessment approach.
- ▪Higher levels of non-HDL cholesterol and ApoB were associated with increased risks for atherosclerotic cardiovascular disease and myocardial infarction.
- ▪The study included 94,398 Danish adults and tracked the occurrence of first heart attack and cardiovascular events over a median follow-up of 13.2 years.
- ▪Each 1-SD increase in non-HDL cholesterol was linked to a 16% increased risk for cardiovascular disease, while a similar increase in ApoB was linked to a 14% increased risk.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Higher levels of non-high-density lipoprotein (non-HDL) cholesterol and apolipoprotein B (ApoB) were each associated with increased risks for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Each marker independently improved risk prediction beyond the information provided by the other, and risk was highest when both marker levels were elevated.METHODOLOGY:Researchers conducted a cohort study to assess whether baseline levels of non-HDL cholesterol and ApoB each added predictive value for ASCVD beyond the other, using data from the Copenhagen General Population Study.They included 94,398 Danish adults recruited between 2003 and 2015 who were not taking lipid-lowering drugs at baseline; 56% were women.Non-HDL cholesterol and ApoB levels were measured…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
